Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2000;87:418-425

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vieillard-Baron, A.
Right arrow Articles by d’Ortho, M.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vieillard-Baron, A.
Right arrow Articles by d’Ortho, M.-P.
Related Collections
Right arrow Remodeling
Right arrow Animal models of human disease
Right arrow Pulmonary circulation and disease
Right arrow Gene therapy
(Circulation Research. 2000;87:418.)
© 2000 American Heart Association, Inc.


Integrative Physiology

Inhibition of Matrix Metalloproteinases by Lung TIMP-1 Gene Transfer or Doxycycline Aggravates Pulmonary Hypertension in Rats

Antoine Vieillard-Baron, Eric Frisdal, Saadia Eddahibi, Isabelle Deprez, Andrew H. Baker, Andrew C. Newby, Patrick Berger, Micheline Levame, Bernadette Raffestin, Serge Adnot, Marie-Pia d’Ortho

From INSERM U492 (A.V.-B., E.F., S.E., I.D., M.L., B.R., S.A., M.-P.d’O.), Faculté de Médecine, Créteil, France; Service de Réanimation Médicale (A.V.-B.) and Service des Explorations Fonctionnelles (B.R.), Hôpital Ambroise Paré, AP-HP, Boulogne, France; Bristol Heart Institute (A.H.B., A.C.N.), University of Bristol, Bristol Royal Infirmary, Bristol, UK; INSERM E-9937 (P.B.), Université Victor Segalen Bordeaux 2, Bordeaux, France; and Service des Explorations Fonctionnelles (S.A., M.-P.d’O.), Hôpital Henri Mondor, AP-HP, Créteil, France.

Correspondence to Marie-Pia d’Ortho, INSERM U492, 8 rue du Général Sarrail, 94010 Creteil, France. E-mail dortho{at}im3.inserm.fr


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Chronic hypoxic pulmonary hypertension (PH) results from persistent vasoconstriction, excess muscularization, and extracellular matrix remodeling of pulmonary arteries. The matrix metalloproteinases (MMPs) are a family of proteinases implicated in extracellular matrix turnover and hence in smooth muscle and endothelial cell migration and proliferation. Because MMP expression and activity are increased in PH, we designed the present study to investigate whether inhibition of lung MMPs in rats subjected to chronic hypoxia (CH) contributes to or protects against vascular remodeling and PH. To achieve lung MMP inhibition, rats exposed to 10% O2 for 15 days were treated with either doxycycline (20 mg/kg per day by gavage starting 2 days before and continuing throughout the CH period) or a single dose of recombinant adenovirus (Ad) for the human tissue inhibitors of metalloproteinases-1 (hTIMP-1) gene (Ad.hTIMP-1, 108 plaque-forming units given intratracheally 2 days before CH initiation). Control groups either received no treatment or were treated with an adenovirus containing no gene in the expression cassette (Ad.Null). Efficacy of hTIMP-1 gene transfer was assessed both by ELISA on bronchoalveolar lavages and by hTIMP-1 immunofluorescence on lung sections. MMP inhibition in lungs was evaluated by in situ zymography and gelatinolytic activity assessment using [3H]gelatin. Rats treated with either doxycycline or Ad.hTIMP-1 had higher pulmonary artery pressure and right heart ventricular hypertrophy more severe than their respective controls. Worsening of PH was associated with increased muscularization and periadventitial collagen accumulation in distal arteries. In conclusion, our study provides compelling evidence that MMPs play a pivotal role in protecting against pulmonary artery remodeling.


Key Words: pulmonary hypertension • gene therapy • inhibitor of metalloproteinases • extracellular matrix • vascular remodeling


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Chronic pulmonary hypertension (PH) results from persistent vasoconstriction and structural remodeling of pulmonary arteries.1 2 Accumulation of connective tissue in vessel wall is an important component of the alterations in PH and results from a complex interplay between synthesis and degradation of extracellular matrix (ECM).3 4 5 ECM protein degradation is an active process dependent on the action of proteases, including matrix metalloproteinases (MMPs). MMPs are identified and subdivided on the basis of their substrate specificity into collagenases, gelatinases, stromelysin, and membrane-type MMPs.6 The importance of MMPs in the development of PH remains unclear. MMPs not only control ECM deposition, but they also facilitate migration and growth of smooth muscle cells (SMCs)7 through their ability to degrade ECM. Mitogenesis of SMCs may also be indirectly stimulated by MMPs through the release of growth factors bound to ECM proteins.8

In rats, reversal of hypoxic PH after return to normoxia is associated with increases in collagenolytic and elastolytic activities, with a rapid reduction in collagen content of pulmonary arteries, suggesting an association between decreased pulmonary artery remodeling and increased MMP activity.5 9 However, gelatinase A (MMP-2) expression and activity may be increased in pulmonary arteries from rats developing PH in response to monocrotaline or to chronic hypoxia.10 11 This suggests that MMPs may contribute to pulmonary artery remodeling, an effect that would be consistent with reported effects of MMPs on systemic arteries12 13 14 in which MMP inhibition limited neointima formation.15 In PH, the effects of MMP inhibition have not yet been studied in vivo, particularly because MMP inhibition has proven difficult to achieve in the lung.

MMP activity is modulated by counterregulatory tissue inhibitors of MMPs (TIMPs).16 TIMP-1 is synthesized by most types of connective tissue cells and inhibits collagenases, stromelysin, and gelatinases.17 We used adenovirus (Ad)-mediated gene transfer to induce overexpression of human TIMP-1 (hTIMP-1) in the lungs with the goal of investigating the effect of chronic MMP inhibition on the development of PH and vascular remodeling in rats subjected to chronic hypoxia. To confirm our results obtained with Ad.hTIMP-1, we also used the same PH model to examine the effect of doxycycline, which has been shown to potently inhibit MMP activity when administered in vivo.18 19


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Study Design
Two sets of experiments were performed in Wistar rats (260 to 280 g body weight, Charles River) exposed to chronic hypoxia. In the doxycycline study, rats received 20 mg/kg doxycycline by gavage per day and were compared with an untreated control group. Doxycycline was started 2 days before hypoxia and continued throughout hypoxia exposure. In the Ad.hTIMP-1 study, rats were treated 2 days before hypoxia with a single intratracheal dose of either a recombinant adenovirus coding for hTIMP-1 (Ad.hTIMP-1, 108 plaque-forming units [pfu]) or an adenovirus with an empty expression cassette (Ad.Null, 108 pfu).

A preliminary study in normoxic conditions was conducted to assess efficiency of gene transfer to the lung after intratracheal Ad.hTIMP-1 instillation.

Treatment With Ad.hTIMP-1
Ad.hTIMP-1 is a replication-deficient recombinant adenovirus serotype 5 vector capable of high-level hTIMP-1 gene expression.20 Ad.Null was used as the control. Intratracheal instillation of 150 µL/rat of diluted Ad.hTIMP-1 or Ad.Null was performed as previously described.21

Evaluation of Gene Transfer Under Normoxic Conditions. Bronchoalveolar lavage (BAL) fluid levels of hTIMP-1 protein were measured 5 days after administration of Ad.hTIMP-1 (5x107 or 108 pfu) or Ad.Null (108 pfu). hTIMP-1 protein was also assayed in BAL fluid 2 (n=3 rats), 5 (n=10), and 15 days (n=8) after an Ad.hTIMP-1 dose (108 pfu).

ELISA detection of hTIMP-1 was carried out on BAL samples (TIMP-1, human ELISA system, Amersham Pharmacia Biotech). The ELISA system used selectively measures hTIMP-1 and does not cross-react with rat TIMP-1.20

Immunocytochemistry was performed on the lungs of normoxic rats 5 days after instillation of Ad.hTIMP-1 or Ad.Null (108 pfu). Antibodies were obtained from Santa Cruz Biotechnology, Inc. (TEBU, Le Perray en Yvelines, France), with the exception of nonrelevant rabbit antibodies to human thyroglobulin that were used as the negative control (Dako).

Exposure of Rats to Chronic Hypoxia and Evaluation of PH and Gelatinase Activity
Rats were exposed to chronic hypoxia (10% to 12% fraction of inspired oxygen) for 15 days, as previously described.22

Hemodynamic Measurements and Assessment of Right Ventricular Hypertrophy
At the end of exposure to hypoxia, pulmonary and systemic arterial pressures were measured, as previously described.23 Finally, the heart was excised and weighed, and the Fulton index (ratio of right ventricular free wall over sum of septum plus left ventricular free wall weight [RV/S+LV]) was calculated.

Assessment of Pulmonary Vascular Remodeling
Five-micrometer-thick lung sections were stained with hematoxylin-phloxin-saffron. In each rat, 30 to 40 intra-acinar arteries were analyzed to assess the distribution and degree of muscularization. Intra-acinar arteries were categorized as muscular, partially muscular, or nonmuscular, as reported.24

Five-micrometer-thick lung sections were also stained with orcein-picroindigo-carmine to measure collagen content. Quantification of the collagen in pulmonary arteries was assessed morphometrically with an image analysis system using Quancoul software (Quant’ Image), as previously described.25

Gelatinase Activity
The pulmonary arteries and lung were excised, frozen in liquid nitrogen, and stored at -80°C for gelatin zymography on homogenates, as previously described.26 They were also fixed in the distended state by infusion of Tissue-Tek OCT compound (Sakura) and stored at -80°C for in situ zymography.27 Free gelatinases activities were also assayed by using the ability of tissue homogenates to degrade 50 µg of [3H]-gelatin.

Statistical Analysis
All results are reported as mean±SEM. The nonparametric Mann-Whitney U test was used for single comparisons of hemodynamic parameters, body weight, heart weight, degree of muscularization, and collagen content between inhibitor-treated and control rats.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
Ad.hTIMP-1 Treatment
Evaluation of In Vivo hTIMP-1 Gene Transfer and Endogenous Gelatinase Activity in Normoxic Rats
As little as 5x107 pfu of Ad.hTIMP-1 induced expression of hTIMP-1 protein detectable in BAL fluid (Figure 1ADown). No hTIMP-1 was found in BAL fluid from the control rats given Ad.Null. The level of hTIMP-1 in BAL fluid increased with the dose of Ad.hTIMP-1. With 108 pfu of either Ad.hTIMP-1 or Ad.Null, mild inflammation characterized by patchy infiltrates of mononuclear cells was seen, with no cell damage, edema, or hemorrhage (data not shown). Because the 108-pfu dose caused minimal inflammation and significant hTIMP-1 protein production in the lung, we used it in further experiments.



View larger version (7K):
[in this window]
[in a new window]
 
Figure 1. hTIMP-1 expression in BAL fluid. A, hTIMP-1 protein expression in BAL fluid from normoxic rats 5 days after intratracheal instillation of Ad.hTIMP-1 (5x107 pfu and 108 pfu, n=5 each) or of Ad.Null (108 pfu, n=5). hTIMP-1 protein level was determined by ELISA. B, Time course of hTIMP-1 protein expression in BAL fluid from normoxic rats at 2 days (D2, n=3), 5 days (D5, n=10), or 15 days (D 15, n=8) after administration of Ad.hTIMP-1 (108 pfu). A and B, Horizontal bars indicate mean values.

As shown in Figure 1BUp, detectable hTIMP-1 protein expression in BAL fluid after administration of 108 pfu Ad.hTIMP-1 was noted on day 2 after dose and was still present 5 and 15 days after dose.

Immunolocalization of hTIMP-1 on lung sections from Ad.hTIMP-1–treated rats demonstrated expression of hTIMP-1 by bronchoalveolar epithelial cells (Figure 2BDown). Staining for hTIMP-1 protein was diffuse throughout the lung, albeit heterogeneous. No fluorescence was detectable on lung sections of Ad.Null-treated rats (Figure 2ADown).



View larger version (44K):
[in this window]
[in a new window]
 
Figure 2. hTIMP-1 detection by immunochemistry on lung sections in rats 5 days after intratracheal administration of Ad.Null (A) or Ad.hTIMP-1 (B and C). Slides were pretreated with Evan’s Blue to transform green autofluorescence of elastic fibers to a red stain. Specific staining for hTIMP-1 was seen as green fluorescence in the bronchoalveolar epithelium (B). No hTIMP-1 was detected in control rats treated with Ad.Null (A) or when a nonrelevant antibody directed to human thyroglobulin was used (C). Bar=20 µm.

To ascertain that Ad.hTIMP-1 administration did not alter endogenous gelatinase production, BAL fluid gelatinase levels were measured using gelatin zymography. Total gelatinase activity in BAL fluid did not differ among Ad.hTIMP-1–, Ad.Null-, and vehicle-treated rats (data not shown).

Effects of Ad.hTIMP-1 on Chronic Hypoxic PH
Ad.hTIMP-1 and Ad.Null (108 pfu) were well tolerated. No deaths or symptoms of respiratory failure were observed in the rats exposed to chronic hypoxia.

Hemodynamic Measurements and Assessment of Right Ventricular Hypertrophy After Exposure to Chronic Hypoxia
After 15 days of exposure to hypoxia, although there was a trend toward higher pulmonary artery pressure in the Ad.hTIMP-1–treated than in the Ad.Null-treated rats (Figure 3ADown), the difference did not reach statistical significance (P=0.06). Body weight, systemic arterial pressure, and heart rate were similar in both groups (data not shown). Right ventricular hypertrophy assessed by the Fulton index was significantly more marked in the Ad.hTIMP-1–treated rats than in the Ad.Null-treated rats (P<0.01, Figure 3BDown), whereas the ratio of left ventricular plus septum weight divided by body weight was similar in the 2 groups (data not shown).



View larger version (14K):
[in this window]
[in a new window]
 
Figure 3. Pulmonary artery pressure and right ventricular hypertrophy in Ad.hTIMP-1 study. A, Mean pulmonary artery pressure in rats exposed to chronic hypoxia and treated with 108 pfu Ad.hTIMP-1 (n=10). Corresponding control group was exposed to chronic hypoxia and received 108 pfu Ad.Null (n=10). B, Right ventricular hypertrophy as assessed on the basis of the Fulton index (RV/S+LV) in rats exposed to chronic hypoxia and treated with 108 pfu Ad.hTIMP-1 (n=10). The corresponding control group was exposed to chronic hypoxia and received 108 pfu Ad.Null (n=10). Values are mean±SEM. **P<0.05.

Structural Remodeling of Distal Pulmonary Arteries
Treatment with Ad.hTIMP-1 was associated with a significant increase in distal pulmonary artery muscularization (Figure 4Down) compared with the control exposed to similar hypoxic conditions (P<0.001).



View larger version (45K):
[in this window]
[in a new window]
 
Figure 4. A, Muscularization of pulmonary peripheral vessels in Ad.hTIMP-1 study. A significant increase in muscularization of small pulmonary arteries was found in Ad.hTIMP-1–treated rats (n=10) compared with Ad.Null-treated rats (n=10). Percentages of nonmuscular (NM), partially muscular (PM), and muscular (M) arteries were determined at the alveolar duct and alveolar wall levels. Values are mean±SEM. **P<0.05. B, Morphometric quantification of collagen content in pulmonary arteries by an image analysis system using Quancoul software on lung sections stained with orcein-picroindigo-carmine. Collagen accumulation was increased in pulmonary arteries from rats treated with Ad.hTIMP-1 (n=10) compared with control (n=10). Values are mean±SEM percentages for collagen in pulmonary arteries. **P<0.05. C, Periadventitial collagen accumulation in pulmonary arteries in rats exposed to chronic hypoxia and treated with either Ad.Null (top) or Ad.hTIMP-1 (bottom). Lung section stained with orcein-picroindigo-carmine from the Ad.hTIMP-1–treated rat shows periadventitial collagen accumulation (in blue) in pulmonary arteries. Magnification x250.

Collagen content was significantly increased in pulmonary arteries from rats treated with Ad.hTIMP-1 compared with control (P<0.0001, Figure 4BUp). This increase was localized in the periadventitial compartment of the vessels (Figure 4CUp).

Evaluation of Gelatinase Activity
Gelatinase activity as evaluated by in situ zymography was dramatically decreased in lung from rats treated with Ad.hTIMP-1 compared with controls (Figure 5BDown). There was a decrease in free gelatinolytic activity (degradation of [3H]gelatin) found in lung and pulmonary arteries from rats treated by Ad.hTIMP-1 compared with Ad.Null-treated rats, although this was not significant (Figure 5ADown).



View larger version (46K):
[in this window]
[in a new window]
 
Figure 5. Gelatinolytic activity assessment in Ad.hTIMP-1 study. A, Free gelatinase activity using [3H]gelatin, in pulmonary arteries (PA) and lungs from Ad.hTIMP-1–treated rats (n=7) and Ad.Null-treated rats (n=7). Values are mean±SEM (micrograms of gelatin degraded over 48 hours per milligram of tissue). B, In situ zymography on lung sections from rats exposed to chronic hypoxia and treated with Ad.hTIMP-1. Gelatinase activity was dramatically decreased in the MMP inhibitor–treated rats (bottom) compared with controls (top). Bar=100 µm.

Total gelatinase activity in lungs (Figure 1Up online, available in online-only data supplement at http://www.circresaha.org) and in pulmonary artery homogenates (data not shown), as measured by conventional zymographic analysis SDS-PAGE to separate MMPs from their inhibitors, was similar in rats treated with Ad.hTIMP-1 and Ad.Null.

Doxycycline Treatment
Effects of Doxycycline Treatment on Chronic Hypoxic PH
Hemodynamic Measurements and Assessment of Right Ventricular Hypertrophy After Exposure to Chronic Hypoxia
After 15 days of exposure to hypoxia, pulmonary artery pressure was higher in the doxycycline-treated rats than in their respective controls (P<0.05, Figure 6ADown). Body weight, systemic arterial pressure, and heart rate were similar in all groups (data not shown). However, the Fulton index was not significantly increased in the doxycycline-treated rats compared with their controls (Figure 6BDown). The ratios of heart weight or left ventricular plus septum weight divided by body weight were significantly lower in the doxycycline-treated rats than in the control rats (2.42±0.08 versus 2.67±0.07 and 1.71±0.05 versus 1.87±0.05, respectively; P<0.05), whereas right ventricular weight divided by body weight was not significantly different between the 2 groups (0.71±0.04 versus 0.80±0.04).



View larger version (14K):
[in this window]
[in a new window]
 
Figure 6. Pulmonary artery pressure and right ventricular hypertrophy doxycycline study. A, Mean pulmonary artery pressure in rats exposed to chronic hypoxia and treated with doxycycline (n=10). Corresponding control group was exposed to chronic hypoxia and received no treatment (n=10). B, Right ventricular hypertrophy as on the basis of the Fulton index (RV/S+LV) in rats exposed to chronic hypoxia and treated with doxycycline (n=10). The corresponding control group was exposed to chronic hypoxia and received no treatment (n=10). Values are mean±SEM. **P<0.05.

Structural Remodeling of Distal Pulmonary Arteries
Treatment with doxycycline was associated with a significant increase in distal pulmonary artery muscularization compared with the controls (P<0.001, Figure 7ADown).



View larger version (49K):
[in this window]
[in a new window]
 
Figure 7. A, Muscularization of pulmonary peripheral vessels in doxycycline study. A significant increase in muscularization of small pulmonary arteries was found after treatment by doxycycline. Percentages of nonmuscular (NM), partially muscular (PM), and muscular (M) arteries were determined at the alveolar duct and alveolar wall levels. Values are mean±SEM. **P<0.05. B, Morphometric quantification of collagen content in pulmonary arteries by an image analysis system using Quancoul software on lung sections stained with orcein-picroindigo-carmine. Collagen accumulation was increased in pulmonary arteries from rats treated with doxycycline (n=10) compared with control (n=10). Values are mean±SEM percentage for collagen in pulmonary arteries. **P<0.05. C, Periadventitial collagen accumulation in pulmonary arteries in rats exposed to chronic hypoxia and treated with either control (top) or doxycycline (bottom). Lung section stained with orcein-picroindigo-carmine from the doxycycline-treated rat shows periadventitial collagen accumulation (in blue) in the pulmonary arteries. Magnification x250.

Collagen content was significantly increased in pulmonary arteries from rats treated with doxycycline compared with control (P<0.05, Figure 7BUp). This increase was localized in the periadventitial compartment of the vessels (Figure 7CUp).

Evaluation of Gelatinase Activity
Gelatinase activity as evaluated by in situ zymography was decreased in pulmonary arteries (Figure 8BDown) and in lung sections (data not shown) from rats treated with doxycycline. There was a decrease in free gelatinolytic activity (degradation of [3H]gelatin) found in pulmonary arteries from rats treated by doxycycline compared with control rats, although this was not significant (Figure 8ADown).



View larger version (60K):
[in this window]
[in a new window]
 
Figure 8. Gelatinolytic assessment in doxycycline study. A, Free gelatinase activity using [3H]gelatin, in pulmonary arteries from doxycycline-treated rats and controls. Values are mean±SEM (micrograms of gelatin degraded over 48 hours per milligram of tissue). B, In situ zymography on pulmonary artery sections in rats exposed to chronic hypoxia and treated with doxycycline. Gelatinase activity was decreased in the MMP inhibitor–treated rats (bottom) compared with controls (top). Bar on left=100 µm; bar on right=60 µm.

Total gelatinase activity in lungs (Figure 1Up online, available in online-only data supplement at http://www.circresaha.org) and in pulmonary artery homogenates (data not shown), as measured by conventional zymographic analysis SDS-PAGE, was similar in rats treated with doxycycline and in their controls.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
We found that inhibition of lung MMPs during exposure to chronic hypoxia in rats was associated with exacerbation of PH and vascular remodeling. Either of 2 MMP-inhibiting treatments, namely adenovirus-mediated hTIMP-1 lung gene transfer and doxycycline, increased muscularization and collagen accumulation in small pulmonary arteries. These results support a key role of MMPs in limiting ECM and smooth muscle accumulation during the development of PH.

Previous observations have suggested that ECM alterations produced by proteolytic enzymes contribute to the process of vascular remodeling.28 In experimental models of systemic vascular injury induced by endothelial denudation, MMP inhibition has been found to delay or diminish neointima formation and arterial wall thickening.12 15 29 In pulmonary arteries, increases in MMP expression and activity have been demonstrated during both the development10 11 and the reversal of PH.9 The observation that pulmonary arteries undergo active remodeling during PH development2 has suggested that developing pharmacological inhibitors of this remodeling process may be an effective treatment strategy. However, few data are available on the role of MMPs in PH, in part because no pharmacological tools capable of inhibiting MMP activity selectively in the lung were available.

In the present study, we used a previously described adenovirus vector containing hTIMP-1 cDNA,20 which we administered intratracheally to rats before exposure to hypoxia. Several studies using intratracheal administration of adenovirus vectors found that transgene expression was mainly located within airway and alveolar epithelial cells.30 On the basis of earlier results with this route of administration,21 31 we reasoned that adenovirus-mediated gene transfer of the hTIMP-1 gene to the lung would expose pulmonary arteries to increased levels of TIMP-1. After intratracheal administration of Ad.hTIMP-1 (108 pfu), the hTIMP-1 protein was expressed by bronchoalveolar epithelial cells throughout the lung sections. Our investigation of hTIMP-1 protein levels in BAL fluid showed that hTIMP-1 overexpression persisted throughout the 15 days of exposure to hypoxia. The ability of hTIMP-1 to inhibit MMP activity was confirmed by our in situ zymography results showing a dramatic decrease in free gelatinase activity in the pulmonary arteries and lungs from Ad.hTIMP-1–treated rats compared with Ad.Null-treated rats. In aggregate, our results strongly suggest that adenovirus gene transfer was successful in inducing a sustained shift of the proteolytic balance toward MMP inhibition by TIMP in the lung.

Our most striking finding is that 2 different treatment strategies aimed at inhibiting lung MMP activity, namely adenovirus-mediated hTIMP-1 gene transfer and doxycycline, led to similar exacerbation of pulmonary artery remodeling and PH in rats subjected to chronic hypoxia. This finding supports a protective effect of MMPs against the development of hypoxic PH. The most likely mechanism underlying this effect is prevention by MMPs of ECM accumulation within pulmonary arteries. Other studies found evidence that pulmonary artery wall thickening during the development of PH was related in part to increased connective tissue protein synthesis,5 32 a possibility consistent with our finding that both lung hTIMP-1 overexpression and doxycycline were associated with excess periadventitial collagen in small pulmonary arteries. Also, Kerr et al33 reported that administration of the collagen synthesis inhibitor cis-hydroxyproline reduced hypoxia-induced PH and prevented increases in arteriole wall thickness and decreases in arteriole lumen diameter. Moreover, Thakker-Varia et al34 reported that the activity of collagenases found predominantly in the media and adventitia contributed to the breakdown of collagen in pulmonary artery walls observed during early reversal of hypoxic PH.

MMP inhibition was associated not only with greater ECM accumulation in artery walls, but also with increased muscularization of intra-acinar arteries. This finding was somewhat unexpected, because several studies have suggested that ECM degradation may be essential to SMC migration and proliferation.12 35 Moreover, synthetic MMP inhibitors have been shown to inhibit proliferation of SMCs from rabbit aorta explants.7 Localized TIMP overexpression in luminal cells transduced with either the same recombinant adenovirus as that used in the present study29 or with TIMP-2 adenovirus36 potently inhibited neointima formation in human saphenous veins in an organ culture model.29 36 The recent finding of more severe neointimal formation after femoral artery injury in TIMP-1–deficient mice further supports an aggravating role of MMPs in systemic artery remodeling.37 The apparent discrepancy between these studies and our results may be ascribable to differences across the considered vascular beds. In particular, neointima formation in pulmonary arteries occurs only when the pressure reaches systemic levels.38 Increased pulmonary artery muscularization in response to MMP inhibition may be a direct consequence of increased ECM deposition; an increase in the number of cell-ECM contacts may stimulate SMC growth by increasing the mechanical tension transmitted across integrins.3 Alternatively, the increased muscularization may be an adaptive response to the increased resistance to flow produced by ECM accumulation. This latter hypothesis is supported by a report that SMC proliferation increased in response to a rise in pulmonary artery wall tension.39

Our results might contrast with the recent studies by Cowan et al40 41 showing that serine proteinase and MMP activation are critical for inducing the proliferative and migratory events that characterize pulmonary vascular remodeling secondary to monocrotaline administration. In these studies, regression of pulmonary artery hypertension was observed after treatment with a serine elastase inhibitor, involving a loss of both cellular and matrix components. In the present study, aggravation of hypoxic PH was induced by treatment with doxycycline or lung overexpression of hTIMP-1, which both inhibit MMPs but not serine elastase. The experimental models also differ because monocrotaline-induced PH is associated with a marked inflammatory component not observed during exposure to chronic hypoxia. It is therefore likely that differences in the experimental models used and in the proteolytic enzymes targeted by the inhibitors may explain the apparent contrasting results between these studies.

The absence of difference in the Fulton index between doxycycline-treated rats and controls contrasts with the observation that pulmonary artery pressure and muscularization were increased in the doxycycline-treated group. However, one hypothesis could be that inhibition of MMPs by the systemic route could influence heart growth. The heart/body weight and left ventricular weight+sum of septum/body weight ratios support this hypothesis, as they were significantly lower in the doxycycline-treated rats than in the control rats, whereas right ventricle/body weight ratio was not. We are currently investigating this hypothesis. From our point of view, demonstration of increased pulmonary artery pressure and muscularization after inhibition of MMPs is a strong argument for aggravation of PH.

In conclusion, our study provides strong support for the hypothesis that MMPs may play a crucial role in pulmonary artery remodeling and may partially protect against PH development, as MMP inhibition led to aggravated PH. In view of recent results on treatment of monocrotaline-induced PH by elastase inhibition, further studies are clearly needed to evaluate the effect of MMP inhibition in such a model to develop new therapeutic strategies.


*    Acknowledgments
 
This study received financial support from INSERM and from Medical Research Council Grants SPG9324197 (to A.N.) and G9901227 (to A.B.). We thank Dr N. Ferry (Laboratoire de Thérapie Génique, Hôpital Hotel Dieu, Nantes, France) for performing the adenovirus amplification. We thank Dr P. Lemarchand (INSERM U 25, Faculté de Médecine Necker, Paris, France) for generously donating the control adenovirus.

Received February 22, 2000; revision received July 27, 2000; accepted July 27, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 

  1. Heat D. The pathology of pulmonary hypertension. Eur Respir Rev. 1993;3:555–558.
  2. Rabinovitch M, Gamble W, Nadas AS, Miettinen OS, Reid L. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol. 1979;236:H818–H827.[Abstract/Free Full Text]
  3. Lee KM, Tsai KY, Wang N, Ingber DE. Extracellular matrix and pulmonary hypertension: control of vascular smooth muscle cell contractility. Am J Physiol. 1998;274:H76–H82.[Abstract/Free Full Text]
  4. Meyrick B, Reid L. Hypoxia-induced structural changes in the media and adventitia of the rat hilar pulmonary artery and their regression. Am J Pathol. 1980;100:151–178.[Abstract]
  5. Poiani GJ, Tozzi CA, Yohn SE, Pierce RA, Belsky SA, Berg RA, Yu SY, Deak SB, Riley DJ. Collagen and elastin metabolism in hypertensive pulmonary arteries of rats. Circ Res. 1990;66:968–978.[Abstract/Free Full Text]
  6. Murphy G. In: Royce PM, Steinmann B, eds. Extracellular Matrix Degradation: Connective Tissue and Its Inheritable Disorders. New York, NY: Wiley-Liss; 1993.
  7. Southgate KM, Davies M, Booth RF, Newby AC. Involvement of extra-cellular matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem J. 1992;288:93–99.
  8. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. FASEB J. 1997;11:51–59.[Abstract]
  9. Tozzi CA, Thakker-Varia S, Yu S, Bannett RF, Peng BW, Poiani GJ, Wilson FJ, Riley DJ. Mast cell collagenase correlates with regression of pulmonary vascular remodeling in the rat. Am J Respir Cell Mol Biol. 1998;18:497–510.[Abstract/Free Full Text]
  10. Cowan KN, Jones PL, Rabinovitch M. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res. 1999;84:1223–1233.[Abstract/Free Full Text]
  11. Gest V, d’Ortho MP, Frisdal E, Teiger E, Harf A, Adnot S. Gelatinase A in the vascular remodeling of pulmonary hypertension. Am J Respir Crit Care Med. 1998;157:A590. Abstract.
  12. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539–545.[Abstract/Free Full Text]
  13. Zempo N, Kenagy RD, Bendeck M, Clowes MM, Reidy MA, Clowes AW. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid. J Vasc Surg. 1994;20:209–217.[Medline] [Order article via Infotrieve]
  14. Southgate KM, Fisher M, Banning AP, Thurston VJ, Baker AH. Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. Circ Res. 1996;79:1177–1187.[Abstract/Free Full Text]
  15. Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari ST, Clowes AW. Overexpression of TIMP-1 inhibits vascular smooth muscle cell function in vitro and in vivo. Circ Res. 1996;79:812–820.[Abstract/Free Full Text]
  16. Willenbrock F, Murphy G. Structure-function relationships in the tissue inhibitors of metalloproteinases. Am J Respir Crit Care Med. 1994;150:S165–S170.
  17. Dollery CM, McEwan JR, Henney AM. MMPs and cardiovascular disease. Circ Res. 1995;77:863–868.[Free Full Text]
  18. Golub LM, Ramamurthy NS, McNamara TF. Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med. 1991;2:297–322.[Abstract/Free Full Text]
  19. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase-induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg. 1996;23:336–346.[Medline] [Order article via Infotrieve]
  20. Baker AH, Wilkinson GW, Hembry RM, Murphy G, Newby AC. Development of recombinant adenoviruses that drive high level expression of the human metalloproteinase-9 and TIMP-1 and -2 genes: characterization of their infection into rabbit smooth muscle cells and human MCF-7 adenocarcinoma cells. Matrix Biol. 1996;15:383–395.[Medline] [Order article via Infotrieve]
  21. Janssens SP, Bloch KD, Nong Z, Gerard RD, Zoldhelyi P, Collen D. Adenoviral-mediated transfer of the human endothelial NO synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest. 1996;98:317–324.[Medline] [Order article via Infotrieve]
  22. Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier PE. Loss of endothelium-dependant relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest. 1991;87:155–162.
  23. Partovian C, Adnot S, Eddahibi S, Teiger E, Levame M, Dreyfus P, Raffestin B, Frelin C. Heart and lung VEGF mRNA expression in rats with monocrotaline-or-hypoxia-induced pulmonary hypertension. Am J Physiol. 1998;275:H1948–H1956.[Abstract/Free Full Text]
  24. Rabinovitch M, Gamble W, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol. 1981;240:H62–H72.[Abstract/Free Full Text]
  25. Berger P, Lavallée J, Rouiller R, Laurent F, Marthan R, Tunon-de-Lara JM. Assessment of bronchial inflammation using an automated cell recognition system based on colour analysis. Eur Respir J. 1999;14:1394–1402.[Abstract]
  26. Delclaux C, d’Ortho MP, Delacourt C, Lebargy F, Brun-Buisson C, Brochard L, Lemaire F, Lafuma C, Harf A. Gelatinases in epithelial lining fluid of patients with adult respiratory distress syndrome. Am J Physiol. 1997;272:L442–L451.[Abstract/Free Full Text]
  27. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active protease by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995;9:874–980.[Abstract]
  28. Todoritch-Hunter L, Johnson DJ, Ranger P, Keeley FW, Rabinovitch M. Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline: a biochemical and ultrastructural study. Lab Invest. 1988;58:184–195.[Medline] [Order article via Infotrieve]
  29. George SJ, Johnson JL, Angelini GD, Newby AC, Baker AH. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther. 1998;9:867–877.[Medline] [Order article via Infotrieve]
  30. Lemarchand P, Jones M, Danel C, Yamada I, Mastrangeli A, Crystal R. In vivo adenovirus-mediated gene transfer to lungs via pulmonary artery. J Appl Physiol. 1994;76:2840–2845.[Abstract/Free Full Text]
  31. Partovian C, Adnot S, Raffestin B, Levame M, Lemarchand P, Eddahibi S. Adenoviral mediated VEGF overexpression reduces chronic hypoxic pulmonary hypertension in rats. Am J Respir Crit Care Med. 1999;159:A167. Abstract.
  32. Rabinovitch M. Investigational approaches to pulmonary hypertension. Toxicol Pathol. 1991;19:458–469.[Medline] [Order article via Infotrieve]
  33. Kerr JS, Ruppert CL, Tozzi CA, Neubauer JA, Frankel HM, Yu SY, Riley DJ. Reduction of chronic hypoxic pulmonary hypertension in the rat by an inhibitor of collagen production. Am Rev Respir Dis. 1987;135:300–306.[Medline] [Order article via Infotrieve]
  34. Thakker-Varia S, Tozzi CA, Poiani GJ, Babiarz JP, Tatem L, Wilson FJ, Riley DJ. Expression of matrix-degrading enzymes in pulmonary vascular remodeling in the rat. Am J Physiol. 1998;275:L398–L406.[Abstract/Free Full Text]
  35. Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW. Regulation of vascular smooth muscle migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996;16:28–33.[Abstract/Free Full Text]
  36. George SJ, Baker AH, Angelini GD, Newby AC. Gene transfer of TIMP-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Ther. 1998;5:1552–1560.[Medline] [Order article via Infotrieve]
  37. Lijnen HR, Soloway P, Collen D. TIMP-1 impairs arterial neointima formation after vascular injury in mice. Circ Res. 1999;85:1186–1191.[Abstract/Free Full Text]
  38. Tanaka Y, Schuster DP, Davis EC, Patterson GA, Botney MD. The role of vascular injury and hemodynamics in rat pulmonary artery remodeling. J Clin Invest. 1996;98:434–442.[Medline] [Order article via Infotrieve]
  39. Kolpakov V, Rekhter MD, Gordon D, Wang WH, Kulik TJ. Effect of mechanical forces on growth and matrix protein synthesis in the in vitro pulmonary artery: analysis of the role of individual cell types. Circ Res. 1995;77:823–831.[Abstract/Free Full Text]
  40. Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest. 2000;105:21–34.[Medline] [Order article via Infotrieve]
  41. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6:698–702.[Medline] [Order article via Infotrieve]



This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
L. Vinet, P. Rouet-Benzineb, X. Marniquet, N. Pellegrin, L. Mangin, L. Louedec, J.-L. Samuel, and J.-J. Mercadier
Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction
Am J Physiol Heart Circ Physiol, July 1, 2008; 295(1): H352 - H360.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
A. M. Reynolds, W. Xia, M. D. Holmes, S. J. Hodge, S. Danilov, D. T. Curiel, N. W. Morrell, and P. N. Reynolds
Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension
Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1182 - L1192.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
P. M. Hassoun
Deciphering the "matrix" in pulmonary vascular remodelling
Eur. Respir. J., May 1, 2005; 25(5): 778 - 779.
[Full Text] [PDF]


Home page
Eur Respir JHome page
H. Lepetit, S. Eddahibi, E. Fadel, E. Frisdal, C. Munaut, A. Noel, M. Humbert, S. Adnot, M-P. D'Ortho, and C. Lafuma
Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension
Eur. Respir. J., May 1, 2005; 25(5): 834 - 842.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
L. T. Vaszar, T. Nishimura, J. D. Storey, G. Zhao, D. Qiu, J. L. Faul, R. G. Pearl, and P. N. Kao
Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats
Physiol Genomics, April 13, 2004; 17(2): 150 - 156.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
L. C. Ginns, D. H. Roberts, E. J. Mark, J. L. Brusch, and J. J. Marler
Pulmonary Capillary Hemangiomatosis With Atypical Endotheliomatosis: Successful Antiangiogenic Therapy With Doxycycline
Chest, November 1, 2003; 124(5): 2017 - 2022.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Herget, J. Novotna, J. Bibova, V. Povysilova, M. Vankova, and V. Hampl
Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats
Am J Physiol Lung Cell Mol Physiol, July 1, 2003; 285(1): L199 - L208.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
E. Azoulay, S. Eddahibi, E. Marcos, M. Levame, A. Harf, B. Schlemmer, S. Adnot, and C. Delclaux
Granulocyte colony-stimulating factor enhances alpha-naphthylthiourea-induced pulmonary hypertension
J Appl Physiol, May 1, 2003; 94(5): 2027 - 2033.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
W. Briest, A. Holzl, B. Rassler, A. Deten, H. A Baba, and H.-G. Zimmer
Significance of matrix metalloproteinases in norepinephrine-induced remodelling of rat hearts
Cardiovasc Res, February 1, 2003; 57(2): 379 - 387.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
S. Eddahibi, N. Morrell, M-P. d'Ortho, R. Naeije, and S. Adnot
Pathobiology of pulmonary arterial hypertension
Eur. Respir. J., December 1, 2002; 20(6): 1559 - 1572.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. Kolb, P. Bonniaud, T. Galt, P. J. Sime, M. M. Kelly, P. J. Margetts, and J. Gauldie
Differences in the Fibrogenic Response after Transfer of Active Transforming Growth Factor-{beta}1 Gene to Lungs of "Fibrosis-prone" and "Fibrosis-resistant" Mouse Strains
Am. J. Respir. Cell Mol. Biol., August 1, 2002; 27(2): 141 - 150.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
E. Frisdal, V. Gest, A. Vieillard-Baron, M. Levame, H. Lepetit, S. Eddahibi, C. Lafuma, A. Harf, S. Adnot, and M-;P. d'Ortho
Gelatinase expression in pulmonary arteries during experimental pulmonary hypertension
Eur. Respir. J., November 1, 2001; 18(5): 838 - 845.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
D. GOUKASSIAN, A. DIEZ-JUAN, T. ASAHARA, P. SCHRATZBERGER, M. SILVER, T. MURAYAMA, J. M. ISNER, and V. ANDRES
Overexpression of p27Kip1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis
FASEB J, September 1, 2001; 15(11): 1877 - 1885.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. P. Cappola, G. M. Felker, W.H. L. Kao, J. M. Hare, K. L. Baughman, and E. K. Kasper
Pulmonary Hypertension and Risk of Death in Cardiomyopathy: Patients With Myocarditis Are at Higher Risk
Circulation, April 9, 2002; 105(14): 1663 - 1668.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions